"
Saudi Consensus for Oral Semaglutide, the Recent Innovation in GLP-1 RAs Era; Consensus Report"
written by Ali Alromaih, Abdullah Alshamrani, Bandar Alharbi, Ibtissam Alharbi, Turki Alharbi, Samia Bokhari, Hussein Elbadawi, Mohammed Almehthel, Abdulghani Alsaeed, Khalid Alyahia, Fatimah Alhowyan, Marc Evans, Roopa Mehta, Emad Issak, Saud Alsifri,
published by
Journal of Diabetes Mellitus,
Vol.13 No.2, 2023
has been cited by the following article(s):
|
[1]
|
Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity
Current Signal Transduction Therapy,
2025
DOI:10.2174/0115743624346660250317013032
|
|
|
|
|
[2]
|
Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study
Diabetes Epidemiology and Management,
2024
DOI:10.1016/j.deman.2024.100209
|
|
|
|
|
[3]
|
Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia
Journal of Medical Economics,
2023
DOI:10.1080/13696998.2023.2277056
|
|
|
|